Skip to main content

Table 1 Comparison of clinical data between patients with primary aldosteronism and Bartter and Gitelman syndrome

From: Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome

Variable

PA group (20 cases)

Gits+Bartter group (37 cases)

P

Sex (male/female)

11/9

19/18

0.792(χ2)

Age, year

38.8 ± 10.1

36.1 ± 14.6

0.467

BMI, kg/m2

24.47 ± 4.19

21.79 ± 4.55

0.033

Albumin, g/L

42.70 ± 3.13

42.29 ± 3.20

0.650

Albumin-corrected serum calcium, mmol/L

2.23 ± 0.11

2.34 ± 0.19

0.019

Serum phosphate, mmol/L

1.09 ± 0.19

1.24 ± 0.21

< 0.01

Serum potassium, mmol/L

3.34 ± 0.54

3.02 ± 0.41

0.017

Serum creatinine, umol/L

61.60 ± 16.32

60.64 ± 16.75

0.837

Serum magnesium, mmol/L

0.88 ± 0.09

0.68 ± 0.17

< 0.01

Serum PTH, pmol/L

11.21 ± 7.10

3.62 ± 3.09

< 0.01

Serum 25-OHVD, nmol/L

36.20 ± 18.57

43.98 ± 21.80

0.183

Serum AKP, U/L

60.5 (55.25, 69.75)

60 (49.5, 68)

0.587

Serum renin, uIU/mL

1.50(0.60, 2.40)

5.4 (2.71, 34.55)

< 0.01

Serum aldosterone, ng/dL

27.00 (16.90, 38.35)

16.9 (12.25, 21.65)

< 0.01

Urinary calcium, mmol/24 h

5.62 (4.24, 7.76)

0.65 (0.46, 1.39)

< 0.01

L1-L4, BMD, g/cm2

1.115 ± 0.153

1.156 ± 0.158

0.351

Femoral neck, BMD, g/cm2

0.872 ± 0.141

0.971 ± 0.154

0.022

Total hip, BMD, g/cm2

0.926 ± 0.148

1.033 ± 0.157

0.016